Capricor Therapeutics, Inc. (FRA:4LN2)
Germany · Delayed Price · Currency is EUR | Market Cap | 467.07M +68.8% |
| Revenue (ttm) | n/a |
| Net Income | -113.28M |
| EPS | -2.16 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 6.94 |
| Previous Close | 6.05 |
| Day's Range | 6.93 - 6.99 |
| 52-Week Range | 2.58 - 30.10 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 13, 2026 |
About Capricor Therapeutics
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and... [Read more]
News
Kaplan Fox Encourages Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to Contact the Firm Before the Deadline on September 28, 2026 for a Leadership Role
Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. (NASDAQ: CAPR) on behalf of investors.
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of September 28, 2026 in Capricor Therapeutics, Inc. Lawsuit - CAPR
NEW YORK, Aug. 25, 2026 (GLOBE NEWSWIRE) -- SueWallSt notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) that a class action has been filed on behalf of shareholders who purchased securi...
Capricor Therapeutics upgraded to Outperform from Perform at Oppenheimer
Oppenheimer upgraded Capricor Therapeutics (CAPR) to Outperform from Perform with a $54 price target following yesterday’s regulatory update and further color from a follow-up call with the CEO. The f...
Wainwright says Capricor’s regulatory risk still high after FDA PDUFA extension
H.C. Wainwright notes that Capricor Therapeutics (CAPR) announced that the FDA extended the PDUFA target action date for deramiocel from August 22 to November 22, following submission of a major…
US FDA extends review of Capricor's muscle disorder therapy by three months
Capricor Therapeutics said on Monday that the U.S. Food and Drug Administration had extended the review of its experimental cell therapy for Duchenne muscular dystrophy by three months.
Capricor says FDA extends action date for Deramiocel for amendment review
Capricor Therapeutics (CAPR) announced that the U.S. Food and Drug Administration has extended the Prescription Drug User Fee Act target action date for its biologics license application Deramiocel, a...
Capricor Therapeutics jumps 18% to $7.42 as FDA reviews Deramiocel
09:32 EDT Capricor Therapeutics (CAPR) jumps 18% to $7.42 as FDA reviews Deramiocel
Kaplan Fox Advises Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to Act Before the Lead Plaintiff Deadline on September 28, 2026
NEW YORK, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: ...
Capricor Therapeutics Announces Extension of PDUFA Target Action Date as FDA Continues Review of Deramiocel BLA
– New PDUFA target action date of November 22, 2026 follows submission of additional Phase 3 HOPE-3 data and analyses supporting a refined proposed indication –
Kaos Capital urges Capricor shareholders to support immediate board meeting
Kaos Capital, a significant and growing shareholder of Capricor Therapeutics (CAPR), issued a letter to fellow shareholders calling on them to support an immediate meeting with the Board of Directors…
Kaplan Fox Encourages Capricor Therapeutics, Inc. (CAPR) Investors to Contact the Firm Before the Lead Plaintiff Deadline on September 28, 2026
New York, New York--(Newsfile Corp. - August 20, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. ("Capricor" or the "Compan...
CAPR Stock News: Capricor Therapeutics Sued for Securities Fraud over Alleged Misrepresentations and Corresponding 64% Stock Drop
Capricor Therapeutics, Inc. has been sued for securities fraud over alleged misstatements about Deramiocel and the integrity of the clinical data supporting its Biologics License Application leading t...
Capricor Therapeutics reports Q2 EPS (70c), consensus (58c)
“Our priority is, and always has been, to get Deramiocel to the patients and families living with Duchenne who need it most,” said Linda Marban, Ph.D., Chief Executive Officer of…
Capricor Therapeutics expects cash to fund operations for at least 12 months
The Company believes that, based on its current operating plan and financial resources, its available cash, cash equivalents and marketable securities are sufficient to fund its operating capital requ...
Capricor Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald
Cantor Fitzgerald upgraded Capricor Therapeutics (CAPR) to Overweight from Neutral with a price target of $28, up from $3.50.
Cantor upgrades Capricor on ‘major update’ from earnings call
Cantor Fitzgerald last night upgraded Capricor Therapeutics (CAPR) to Overweight from Neutral with a price target of $28, up from $3.50. The Q2 earnings call focused on the negative FDA…
Capricor Therapeutics: FDA ‘willing’ to review BLA amendment, extend PDUFA date
On its Q2 earnings conference call, Capricor Therapeutics (CAPR) said that following discussions with the FDA subsequent to its advisory committee meeting, “we plan to submit an amendment to our…
Capricor jumps 83% after FDA review update, Cantor upgrade
Capricor Therapeutics (CAPR) in premarket trading are up $3.53 to $7.74.
Capricor shares skyrocket as FDA agrees to review new Duchenne drug data
Capricor Therapeutics shares more than doubled in premarket trading on Friday after the company said the U.S. health regulator is willing to review new data on its experimental Duchenne muscular dyst...
Capricor Therapeutics Earnings Call Transcript: Q2 2026
BLA for deramiocel remains under FDA review, with a focus shifting to upper limb function after an advisory committee vote against the cardiomyopathy indication. Q2 2026 saw a net loss of $40.7 million, with commercial and pipeline activities paced pending regulatory clarity.
Capricor Therapeutics Earnings release: Q2 2026
Capricor Therapeutics released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Capricor Therapeutics Quarterly report: Q2 2026
Capricor Therapeutics has published its Q2 2026 quarterly earnings report on August 13, 2026.
Capricor Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Deramiocel Biologics License Application (BLA) under active FDA review HOPE-3 Phase 3 results published in The Lancet; primary endpoint of upper limb function achieved at p=0.029 Cash, cash equivalent...
Kaplan Fox Reminds Capricor Therapeutics, Inc. (CAPR) Investors Seeking Recovery of the Lead Plaintiff Deadline on September 28, 2026
New York, New York--(Newsfile Corp. - August 11, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. ("Capricor" or the "Compan...
CAPR Investor Announcement: Capricor Therapeutics Sued on behalf of Investors to Recover Losses after Clinical Data Leads to 64% Stock Drop
Capricor Therapeutics, Inc. has been sued for securities fraud over alleged misstatements about Deramiocel and the integrity of the clinical data supporting its Biologics License Application leading t...